|Bid||16.300 x 900|
|Ask||16.350 x 4000|
|Day's range||16.050 - 16.496|
|52-week range||8.000 - 27.500|
|PE ratio (TTM)||N/A|
|Earnings date||7 Aug 2018 - 13 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.20|
In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.
After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.
Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc. (SGMO) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell disease. Bioverativ and Sangamo are developing BIVV003 as part of an exclusive worldwide collaboration to develop and commercialize gene-edited cell therapies for sickle cell disease and beta thalassemia.
On a per-share basis, the Richmond, California-based company said it had a loss of 23 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Sangamo Therapeutics Inc. shares fell in the extended session Tuesday after the biotech company announced a secondary offering of its stock. Sangamo shares fell 8.5% after hours, following a 1.9% decline to close at $17.80 in the regular session. Sangamo has about 86 million shares outstanding.
If you're an investor who's heard of zinc-finger proteins and gene editing but you aren't sure what it all means, this can help answer your questions.
One big deal -- and two small ones -- Pfizer could make instead of buying Bristol-Myers Squibb.
In May 2017, Sangamo Therapeutics (SGMO) and Pfizer (PFE) announced a collaboration for hemophilia A gene therapy that includes SB-525, which is one of Sangamo Therapeutics’ four lead product candidates. This collaboration is highly synergistic, as it combines Pfizer’s expertise in rare diseases with Sangamo Therapeutics’ expertise in genomic therapies.
On January 3, 2018, Pfizer (PFE) and Sangamo Therapeutics (SGMO) announced a collaboration for developing a potential gene therapy. ALS (or Lou Gehrig’s disease) and FTLD are neurodegenerative disorders caused by mutations in the C9ORF72 gene.
Shares of Jounce Therapeutics and Sangamo Therapeutics were both hit hard last week by the marketwide sell-off. This dip is likely to prove temporary in both cases, however.
Glancy Prongay & Murray LLP announces an investigation on behalf of Sangamo Therapeutics, Inc. investors concerning the Company and its directors’ and officers’ possible violations of state laws.
Zacks Investment Ideas feature highlights: Alibaba, NVIDIA, Edwards Lifesciences, Sangamo Therapeutics and bluebird bio